ChemPartner PharmaTech Co

ChemPartner PharmaTech Co EBITDA per Share

The EBITDA per Share of ChemPartner PharmaTech Co (300149.SZ) as of Oct 26, 2026 is 0.08 CNY. In the previous year, EBITDA per Share was -0.05 CNY — a change of -264.89% (higher).

EBITDA per Share

0.08CNY

YoY

-264.89%

Last updated:

EBITDA per Share of ChemPartner PharmaTech Co is 2025 0.08 CNY. EBITDA per Share of ChemPartner PharmaTech Co was 2024 -0.05 CNY. It decreases by -264.89% higher compared to the previous year.

The ChemPartner PharmaTech Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
0.11 CNY
Jan 1, 2018
0.44 CNY
Jan 1, 2019
0.49 CNY
Jan 1, 2020
0.51 CNY
Jan 1, 2021
0.30 CNY
Jan 1, 2022
-0.10 CNY
Jan 1, 2024
-0.05 CNY
Jan 1, 2025
0.08 CNY
The ChemPartner PharmaTech Co EBITDA per Share history
YEAREBITDA per ShareYoY
0.08CNY-264.89%
-0.05CNY-53.99%
-0.10CNY-135.07%
0.30CNY-42.22%
0.51CNY+4.00%
0.49CNY+12.59%
0.44CNY+279.86%
0.11CNY-22.01%
0.15CNY+8.32%
0.14CNY+44.17%
0.09CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ChemPartner PharmaTech Co Stock analysis

What does ChemPartner PharmaTech Co do? ChemPartner PharmaTech Co., Ltd. generates revenue through the research, development, production, and sale of prebiotic products, primarily fructooligosaccharides and galactooligosaccharides. The company markets its products under the brand names FOS and GOS, targeting the nutrition and health, dairy, beverage, bakery, and functional snack food industries. Domestic distribution dominates, with South China as the core market, serving manufacturers of food and health products. The firm's product portfolio focuses on fructooligosaccharides and galactooligosaccharides, sold as FOS and GOS, which are integrated into various consumer goods. These prebiotics are essential ingredients in dairy, beverages, baked goods, and functional snacks, meeting demand from food producers seeking health-enhancing additives. South China remains the primary sales region, aligning with the company's domestic market strategy. ChemPartner PharmaTech's revenue streams derive from B2B sales to food and beverage manufacturers, particularly those producing nutrition and health products, dairy, and functional snacks. The company's brands FOS and GOS are positioned as key ingredients for health-focused consumer goods, with sales concentrated in South China, the main market for its domestic distribution network. ChemPartner PharmaTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ChemPartner PharmaTech Co stock

EBITDA per Share of ChemPartner PharmaTech Co is 0.08 CNY in 2025.

EBITDA per Share of ChemPartner PharmaTech Co changed from -0.05 CNY to 0.08 CNY, representing a -264.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share ChemPartner PharmaTech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ChemPartner PharmaTech Co

All Key Metrics — ChemPartner PharmaTech Co